<DOC>
	<DOCNO>NCT01487551</DOCNO>
	<brief_summary>The primary objective study change disease related biomarkers patient progressive SSc treatment ABR-215757 . The secondary objective assess safety tolerability ABR-215757 , assess disease activity quality life ( QoL ) treatment ABR-215757 ass plasma level ABR-215757 study .</brief_summary>
	<brief_title>An Open-Label Study Evaluate Biomarkers Safety Systemic Sclerosis Patients Treated With ABR-215757 ( Paquinimod )</brief_title>
	<detailed_description>This open label single arm Phase II study patient progressive SSc . Patients treat ABR-215757 8 week . Assessment biomarkers , disease activity safety parameter perform treatment . Patients offer continue open label extension .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>1 . Age ≥ 18 year time signing informed consent form 2 . Clinical Diagnosis SSc accord ACR criterion 3 . Progressive SSc fulfil least one following : STPR ( Skin Thickness Progression Rate ) ≥ 40 , calculate mRSS screen divided time ( year ) since start skin involvement . report patient ( Denton 2007 ) Worsening mRSS within last 6 month judge physician together patient , involvement least two new anatomical site define mRSS score ( e.g . upper arm thorax ) progression least two point least two anatomical site define mRSS 4 . Presence SSc skin lesion one forearm 5 . Modified Rodnan Skin score ( mRSS ) ≥16 baseline 6 . ANApositive 1 . Ongoing Severe SSc manifestation , pulmonary arterial hypertension ( PAH ) dyspnea NYHA III , scleroderma renal crisis 2 . Vital capacity &lt; 60 % measure within 6 month prior first dose study medication 3 . GFR &lt; 30 % normal measure within 6 month prior first dose study medication 4 . Treatment Rituximab within 12 month biologic agent within 6 month , Mycophenolate mofetil ( MMF ) Cyclophosphamide within 6 month , Methotrexate , Azathioprine immunosuppressant within 3 month prior first dose study medication 5 . History myocardial infarction current uncontrolled angina , severe uncontrolled ventricular arrhythmia , symptomatic congestive heart failure , unstable angina pectoris , electrocardiographic evidence acute ischemia . 6 . Marked baseline prolongation QT/QTc interval ( eg , repeated demonstration QTc interval &gt; 450 millisecond 7 . History additional risk factor torsade de pointes ( eg , heart failure , hypokalemia , family history long QT syndrome ) 8 . Treatment concomitant medication prolong QT interval . 9 . History , current ischemic CNS disease 10 . Current malignancy . A 5year cancerfree period require exception skin basal squamous cell carcinoma cervical cancer situ excise 11 . Current severe infection 12 . Known positive serology HIV active latent hepatitis infection . 13 . Treatment endothelin receptor antagonist within 6 week prior first dose study medication 14 . Drug abuse 15 . Major surgery within 3 week prior study entry 16 . Known suspected hypersensitivity ABR215757 excipients 17 . Female patient childbearing potential use medically accept safe method contraception . All female patient childbearing potential must negative urine pregnancy test Screening Baseline Visits . As interaction study ABR215757 hormonal contraceptive yet perform , woman use hormonal contraceptive contraceptive pill , must also use complementary contraceptive device , i.e . barrier method , treatment period least 1 month thereafter 18 . Female patient childbearing potential pregnant lactating . 19 . Simultaneous participation participation within 4 month 5 half life ( whichever longer ) prior study entry study involve investigational drug experimental therapy . 20 . Other significant , unstable medical disease relate SSc investigator 's opinion would confound study result put patient risk 21 . Patients likely receive oral intravenous steroid immunosuppressant nonSSc condition study duration , confound study result . 22 . Vaccination within 4 week prior first dose study medication . Study Drug ( ) : ABR215757</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Systemic sclerosis</keyword>
	<keyword>Biomarkers</keyword>
</DOC>